2025 ACCP Virtual Journal Club Webinar: Safety, Tolerability & Pharmacokinetics of Oral Doses of the Sirtuin 6 Activator SP-624 - ON DEMAND

Live Session: Tuesday, March 18^th, 2025, from 12:00 to 1:00 PM ET

On Demand: March 18th, 2025 to March 18th, 2028

Why is this webinar important to your practice? 

Learners that complete this webinar will gain knowledge about a First-in-Class drug with a novel mechanism of action. SP-624 (generic name forvisirvat) is a small molecule activator of the sirtuin (SIRT) 6 enzyme. SIRT6 is a NAD+ dependent histone deacetylase and is believed to be the first activator of the enzyme tested in human clinical trials. It is currently being assessed in a Phase 2b/3 study for the treatment of major depressive disorder. The webinar presents data from single ascending dose and multiple ascending dose studies conducted in healthy male and female subjects. The safety, tolerability and pharmacokinetics after single multiple doses of forvisirvat will be reviewed.

Target Audience:

Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals, including Clinical Pharmacologists and Allied Health Services, who are involved or interested in the dosing of Sirtuin 6 Activator SP-624.

Learning Objectives

After completing this activity, the learner will be able to:

• Describe the pharmacokinetics of SP-62;
• Identify key characteristics of dose estimation via ascending dose response of Sirtuin 6 Activator;
• Describe the safety assessments based on the adverse events, serious adverse events and treatment emergent adverse events (TEAEs) of Sirtuin 6 Activator;
• Discuss the use of pharmacokinetics in early drug development.